tbuckley/cabot-search huggingface dataset:
Response rates to hepatic arterial infusion (HAI) pump therapy in patients with metastatic colorectal cancer liver metastases (mCRC LM) after progression on all standard chemotherapies.
Authors: Andrea Cercek, Ariel Aguilo, Jill Gluskin, Joanne F. Chou, Diane Lauren Reidy, Leonard Saltz, Cara Siegel, Marinela Capanu, William R. Jarnagin, Ronald P. DeMatteo, Peter J. Allen, T. Peter Kingham, Yuman Fong, Michael Ian D'Angelica, Nancy E. Kemeny
Journal: Journal of Clinical Oncology (2014)

3623 Background: To evaluate the overall response rate of HAI with floxuridine (FUDR) in the refractory setting in patients with mCRC LM. Methods: After obtaining an IRB waiver a computerized search was performed for patients with mCRC treated with 5FU, oxaliplatin and irinotecan +/- EGFR and VEGF inhibitor from 2003-2012 . Charts were reviewed to ensure patients (pts); had received all standard therapies prior to HAI pump placement, all pts received HAI FUDR and that no new systemic targeted or cytotoxic therapies were used with HAI pump. Imaging was re-reviewed for confirmation of progression prior to HAI pump placement and for best response using RECIST 1.1 criteria. Results: 75 pts were identified; of these 23 had radiographic disease progression on all standard chemotherapies (5FU, irinotecan and oxaliplatin) prior to having a pump placed. Of the 23 evaluable pts, the median age was 53 (range 37-75). Six pts had low volume extrahepatic metastases at the time of pump placement. The overall response rate (ORR) was 8/23 (35%); 10/23 (43%) pts had stable disease (SD). The median duration of SD was 4 months (range 1-10). Median follow up, measured from the date of HAI initiation, was 24 months and median overall survival (OS) was 22 months (95% CI 13-16). The median hepatic progression free survival (hPFS) was 4.5 months [CI: 3.8-6.7]. Thirteen pts developed extrahepatic disease progression (including 5 pts with preexisting extrahepatic disease). The median overall PFS was 3.9 months [95% CI 2.24-5.33]. Median number of HAI treatments was 4 cycles (range 1-13). Six out of 23 (26%) pts required a 50-75% dose reduction by the second cycle due to elevated liver function tests and 18/23 (78%) required a dose reduction after the 3rd cycle. No pts required stents or developed long term liver or biliary toxicity. Conclusions: In a cohort of 23 patients with mCRC LM, refractory to all standard agents, treatment with HAI FUDR resulted in an ORR by RECIST 1.1 of 35% and median OS of 22 months. Further studies focusing on locoregional therapy in patients with liver predominant disease are warranted. Studies to molecularly characterize these tumors are ongoing.
Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).
Authors: J. R. Infante, G. S. Falchook, D. P. Lawrence, J. S. Weber, R. F. Kefford, J. C. Bendell, R. Kurzrock, G. Shapiro, R. R. Kudchadkar, G. V. Long, H. A. Burris, K. B. Kim, A. Clements, S. Peng, B. Yi, A. J. Allred, D. Ouellet, K. Patel, P. F. Lebowitz, K. T. Flaherty
Journal: Journal of Clinical Oncology (2011)

CRA8503 The full, final text of this abstract will be available in Part II of the 2011 Annual Meeting Proceedings, distributed onsite at the Meeting on June 4, 2011, and as a supplement to the June 20, 2011, issue of Journal of Clinical Oncology.
Journal of Medical Genetics, London
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.
Authors: Ugo De Giorgi, Karim Rihawi, Michele Aieta, Giovanni Lo Re, Teodoro Sava, Cristina Masini, Valentina Baldazzi, Fabio De Vincenzo, Andrea Camerini, Giuseppe Fornarini, Luciano Burattini, Giovanni Rosti, Luca I. Moscetti, Vincenzo Emanuele Chiuri, Stefano Luzi Fedeli, Vittorio D. Ferrari, Dino Amadori, Umberto Basso
Journal: Journal of Clinical Oncology (2013)

e15615 Background: Lymphopenia is associated with toxicity and outcome in several cancer types. We assessed the association of pre-treatment lymphopenia with toxicity and clinical outcome of elderly patients with metastatic renal cell cancer treated with first-line sunitinib. We evaluated the prognostic factors in these patients. Methods: We reviewed the clinical files of 181 patients aged &gt;70 years with mRCC treated with first-line sunitinib in seventeen Italian Oncology Units from February 2006 to September 2011. Baseline lymphopenia was defined as lymphocyte counts &lt;1,000/µL. Results: Twenty–nine patients (16.0%) had a baseline lymphocyte counts &lt;1,000/µL, and 152 (84%) ≥1,000/µL. No difference between the two groups was reported in overall response rate (p = 0.207), dose reductions (p = 0.740); discontinuations due to adverse events (p = 0.175), overall incidence of grade 3-4 toxicities (p = 0.112) even if more patients in the group with lymphopenia had grade 3-4 neutropenia (p = 0.017), grade 3-4 thrombocytopenia (p = 0.017) and grade 3-4 diarrhea (p = 0.006). In multivariate analysis, performance status and Heng score were predictors of progression-free survival (p = 0.015 and p = 0.0006, respectively), while performance status, Heng score, and lymphopenia were found to be significantly associated with overall survival (p = 0.007, p &lt; 0.0001 and p = 0.023, respectively). Conclusions: Sunitinib appeared safe and active in elderly patients with lymphopenia. Lymphocyte counts is an independent prognostic factor for OS in elderly patients with mRCC treated with first-line sunitinib.
A Practical Treatise on the Bilious Remittent Fever of Jamaica, its Causes and Effects, &amp;c. To which is added, Medical Topography of the different Military Stations in that Colony
Journal: BMJ (1840)

THERE are few medical worKs, from the peruisal of which we have risen with more pleasure and profit than the ex- cellent treatise of Dr. Arnold on the bilious remittent fever of the West Indies.We are niot, perhaps, very compe- tent judges of a work which is exclusively devoted to dis- eases of a tropical climate; but a long literary experience may entitle us to form a general estimate of the merits of any medical treatise, and we have no hesitation in affirm- ing, that the volume now before us is the production of a philosophical mind, -the fruit of long and well-applied observation.The treatise of Dr. Arnold may be divided into two very distinct parts; in the first, he gives a complete history of the bilious remittent fever of Jamaica; in the second, he describes very minutely, and, so far as we are capable of judging, in a very faithful manner, the medical topography of Jamaica.The latter portion will be found well worthy of the attention of those to whom are entrusted the lives and health of their fellow-creatures in those regions where disease is rife, where death seemns to hold undisputed sway; but it is to the former portion, devoted to the yellow fever, that we are now desirous of directing attention.We shall adhere to the order adopted by Dr. Arnold.History of the Disease.-Noparticular description of the disease, as it exists in the West Indies, occurs before the year 1694.The tradition is, that it was imported into Martinico, a few year3 before, by a French ship, which came from Siam, in the East Indies.This fever, however, did not attract much attention until the war, which ended in 1763, during which a dreadfuil mortality prevailed amongst the soldiers.Since then it has spread exteiisively over North and South America, and visited the southern parts of Europe.Symptoms.-Intreating of the symptoms of yellow fever, Dr. Arnold justly remarks, that different diseases have pro- bably been described under this denomination, and that the great variety of seasons, climates, &c.under which it has prevailed, must have impressed corresponding variations on the characters of the disease itself, at different periods, and during different epidemic attacks; hence the apparent discrepancies in the accounts of yellow fever, published by different physicianis.The following, hoNvever, are peculiar to the disease, and are derived from the author's experi- ence, which has extended over a period of twenty-five years.
The Problem of the Nervous Child.
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Combined use of MammaPrint and molecular subtyping profile (BluePrint) to identify subgroups with marked differences in response to neoadjuvant treatment.
Authors: F. De Snoo, P. Roepman, O. Krijgsman, R. A. Bender, R. Bernards, A. Glas
Journal: Journal of Clinical Oncology (2011)

10613 Background: Concordance between the IHC receptor status and the molecular subtype suggests that molecular profiles represent oncogenic processes that are driven by pathways in which ER, PR and HER2 play pivotal roles. It is, therefore, likely that the use of gene expression arrays will enable the identification of previously unappreciated subtypes of breast cancer that differ in clinical outcomes. Methods: The cohort consists of 133 (T1-4, N0-3) breast cancer patients treated with T/FAC neoadjuvant chemotherapy. Genome wide expression data was publicly available and downloaded from http://bioinformatics.mdanderson.org/pubdata.html. The data was used to determine the response to T/FAC neoadjuvant chemotherapy for patients stratified by MammaPrint and molecular subtype (BluePrint). The MammaPrint and BluePrint result were used to subtype the patients into 4 groups: MammaPrint Low-risk/Luminal-type, MammaPrint High-risk/Luminal-type, Basal-type and ERBB2-type. Results: Within this patient cohort, 20% (n=27) were classified as Basal-type, 62% (n=82) as Luminal-type, and 18% (n=24) as ERBB2-type. The overall pCR of this patient cohort was 26% and differed substantially among the subgroups. pCR was observed in 9% of all Luminal-type samples (i.e. 3% of MammaPrint Low Risk/Luminal-type and 11% of MammaPrint High Risk/Luminal-type), in 50% of the ERBB2-type samples and in 56% of the Basal-type samples. The pCR rates observed for the ERBB2-type and Basal-type patient groups were higher compared to classification based on IHC/CISH assessed ER and HER2 receptor status: 50% for ERBB2-type versus 39% for HER2+ and 56% for Basal-type versus 47% for ER-/HER2- samples. Conclusions: We observed marked differences in response to neo-adjuvant treatment in groups stratified by MammaPrint and BluePrint. These findings confirm differences in chemotherapy response among molecular subgroups and indicate that the BluePrint profile described here will help to further establish a clinical correlation between molecular subtyping and treatment response.
BLOOD TESTS FOR PATERNITY
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lumleian Lectures on the Natural History and Diagnosis of Intrathoracic Cancer
Authors: J. R. Bennett
Journal: BMJ (1870)

<h3>Abstract</h3> Memory and learning involve activity-driven expression of proteins and cytoskeletal reorganisation at new synapses, often requiring post-transcriptional regulation a long distance from corresponding nuclei. A key factor expressed early in synapse formation is Msp300/Nesprin-1, which organises actin filaments around the new synapse. How Msp300 expression is regulated during synaptic plasticity is not yet known. Here, we show that the local translation of <i>msp300</i> is promoted during activity-dependent plasticity by the conserved RNA binding protein Syncrip/hnRNP Q, which binds to <i>msp300</i> transcripts and is essential for plasticity. Single molecule imaging shows that Syncrip is associated <i>in vivo</i> with <i>msp300</i> mRNA in ribosome-rich particles. Elevated neural activity alters the dynamics of Syncrip RNP granules at the synapse, suggesting a change in particle composition or binding that facilitates translation. These results introduce Syncrip as an important early-acting activity-dependent translational regulator of a plasticity gene that is strongly associated with human ataxias. <h3>Syncrip regulates synaptic plasticity via <i>msp300</i></h3> Titlow et al. find that Syncrip (hnRNPQ RNA binding protein) acts directly on <i>msp300</i> to modulate activity-dependent synaptic plasticity. <i>In vivo</i> biophysical experiments reveal activity-dependent changes in RNP complex sizes compatible with an increase in translation at the synapse.
Proximity to oil refineries and risk of bladder cancer: A population-based analysis.
Authors: Tamer Dafashy, Daniel Phillips, Mohamed Danny Ray-Zack, Preston Kerr, Yong Shan, Jacques G. Baillargeon, Yong-Fang Kuo, Hemalkumar B Mehta, Stephen Bentley Williams
Journal: Journal of Clinical Oncology (2019)

4538 Background: Exposure to aromatic amines is a risk factor for bladder cancer. Incidence rates according to proximity to oil refineries are largely unknown. We sought to determine proximity of oil refineries and bladder cancer incidence in the State of Texas which is home to the largest number of oil refineries in the United States. Methods: We used the Texas Cancer Registry database to identify patients diagnosed with bladder cancer from January 1, 2001 to December 31, 2014. The U.S. census data from 2010 was used to ascertain overall population size, age and sex distributions. Heat maps of the 28 active oil refineries in Texas were developed. Incidence of bladder cancer were compared according to proximity ( &lt; 10 vs. ≥ 10 miles) to an oil refinery. Risk ratios were adjusted using a Poisson regression model. Results: A total of 45,517 incident bladder cancer cases were identified of which 5,501 cases were within 10 miles of an oil refinery. In adjusted analyses, bladder cancer risk was significantly greater among males vs. females (Relative Risk (RR) 3.41, 95% Confidence Interval (CI), 3.33-3.50), and greater among people living within 10 miles from an oil refinery than those living outside a 10-mile radius from an oil refinery (RR 1.19, 95% CI, 1.08-1.31). Conclusions: People living within 10 miles from oil refineries were at greater risk for bladder cancer. Further research into exposure to oil refineries and bladder cancer incidence is warranted.
Abstract 14686: Behaviour of a Population of Patients with the Sprint Fidelis Lead
Authors: Jamil Bashir, Michael Yamashita, Shahzad S Karim, Stanley Tung, John Yeung-Lai-Wah, Shanta Chakrabarti, Edna Hahn, Shubhayan Sanatani, Karin Humphries, Charlie Kerr
Journal: Circulation (2011)

Background: The Medtronic Sprint Fidelis ICD lead was recalled in October 2007 due to a high rate of fracture. The true incidence, pattern and outcome of lead failure have been controversial subjec...
A Review: Trichloroethylene Metabolites: Potential Cardiac Teratogens
Authors: Paula D. Johnson, Brenda V. Dawson, Stanley J. Goldberg
Journal: Environmental Health Perspectives (1998)

This review is of a series of the authors' studies designed to test the hypothesis that administration of trichloroethylene (TCE), dichloroethylene (DCE), their metabolites, and related compounds are responsible for fetal cardiac teratogenesis when given to pregnant rats during organogenesis.Identification of teratogenic compounds will allow more accurate assessment of environmental contaminants and public health risks.Epidemiologic studies and previous teratogenic studies using chick embryos and fetal rats have reported an increased number of congenital cardiac defects when exposed to TCE or DCE during fetal development.Metabolites of TCE and DCE studied in the drinking-water exposure study include trichloroacetic acid (TCAA), monochloroacetic acid, trichloroethanol, carboxymethylcysteine, trichloroacetaldehyde, dichloroacetaldehyde, and dichlorovinyl cysteine.Varying doses of each were given in drinking water to pregnant rats during the period of fetal heart development.Rats receiving 2730 ppm TCAA in drinking water were the only metabolite group demonstrating a significant increase in the number of cardiac defects in fetuses on a per-litter basis (p= 0.0004 Wilcoxon test and p= 0.0015 exact permutation test).Maternal and fetal variables showed no statistically significant differences between treated and untreated groups.When treated with TCAA the increased cardiac defects, as compared to controls, do not preclude the involvement of other metabolites as cardiac teratogens, but indicates TCAA as a specific cardiac teratogen.Further studies of drinking-water exposure and potential mechanisms of action on the developing heart are proceeding.
Patients and the Habits of House Officers
Authors: Richard D. Adelman
Journal: JAMA (1987)

<h3>To the Editor.—</h3> In the Jan 2,1987, issue of<i>JAMA</i>, the authors of the article entitled "Patient and House Officer Attitudes on Physician Attire and Etiquette" interviewed 200 patients on the general medical services of teaching hospitals, asking by what name they wished to be addressed by their physician. Of these 200, only 36 (18%) wished to be called by their family name. In spite of this low percentage and the statement by the authors that distance is placed when last names are used, the authors concluded that, "since a sizable portion of our patient population would be offended by being addressed by their first names, the more formal approach would thus seem advisable unless the patient specifically requests otherwise." In a recent survey,<sup>2</sup>I reviewed name preference in the family practice setting in 3000 patients. Of the 3000 patients, 63% stated they wished to be addressed by their
Note From the Editor
Authors: Robert Freedman
Journal: American Journal of Psychiatry (2010)

We are writing to inquire about how the Journal handles issues of confl ict of interest, both fi nancial and intellectual.We raise these questions in the interest of stimulating discussion and encouraging greater transparency, not because we believe there is necessarily one right answer to any question.What is the operational basis of the Editor's evaluation for possible infl uence from disclosed fi nancial relationships?Given that such infl uences can be diffi cult for nonspecialists to detect and may operate beyond the awareness of authors themselves, what criteria are used to judge whether infl uence has occurred?1) Is potential confl ict of interest one of the criteria taken into account when inviting authors of editorials or review articles?For example, if faced with a choice of several possible authors, does the Journal give preference to those without potential confl icts of interest, all other factors being equal?2) Does the Journal's confl ict of interest policy take into account so-called intellectual confl ict of interest as well as fi nancial confl ict of interest?Some professional societies are beginning to pay attention to this type of confl ict in relationship to practice guidelines (1).Restrictions on authorship have costs of their own, including exclusion of the contributions of experts in a fi eld, and should not be undertaken lightly.However, the argument for preferring authors without fi nancial relationships with industry seems particularly strong in the case of editorials and reviews, the value of which resides principally in the reliance that readers can place on the opinions of the authors.Advocating norms of this sort is not to suggest that industry relationships are necessarily problematic in themselves, but recognizes that certain activities may be incompatible with playing an active role in developing treatment recommendations for the fi eld, as is the case for the development of DSM-5 (2).